E-MTAB-10057
RNAseq profiling of tumor, tumor-draining-lymph nodes, blood and tumor-associated macrophages of MC38 mice treated with the PI3Kg inhibitor AZD3458 and a combination of AZD3458 and anti-PD-1
RNAseq profiling of AZD3458 monotherapy and combination treatment with anti-PD-1 of whole tumors, isolated tumor macrophages (Mac) (CD45+CD11b+F4/80+), whole blood (PB) and tumor draining lymph nodes (TDLN) were assessed to elucidate further mechanisms leading to enhanced combination activity.
RNAseq profiling of AZD3458 monotherapy and combination treatment with anti-PD-1 of whole tumors, isolated tumor macrophages (Mac) (CD45+CD11b+F4/80+), whole blood (PB) and tumor draining lymph nodes (TDLN) were assessed to elucidate further mechanisms leading to enhanced combination activity.